LDS/Medical Tests/Galleri Multi-Cancer Early Detection Test

Galleri Multi-Cancer Early Detection Test

The Galleri test, offered by GRAIL (www.grail.com), is a multi-cancer early detection blood test used to screen for a signal shared by more than 50 types of cancer. Galleri is a targeted methylation, next-generation sequencing (NGS)-based assay analyzing cell-free DNA (cfDNA) isolated from peripheral blood. Cancer signal detection is the result of machine learning algorithms based on biological information from the samples experienced by the classifier. Galleri checks more than one hundred thousand regions of DNA and over a million DNA methylation sites on cfDNA from each blood sample.

Galleri looks at methylation patterns on cfDNA to determine whether it comes from healthy (normal) or cancer (abnormal) cells to detect a cancer signal. If a cancer signal is detected, the cfDNA is further analyzed, to determine how closely the methylation pattern matches the patterns of 21 possible Cancer Signal Origins (CSOs) to predict one or two CSOs. The predicted CSO provides information about the tissue type or organ associated with the Cancer Signal. The CSO labels are designed to help the provider determine the next steps for diagnostic evaluation.

Cancer is one of the leading causes of death worldwide. Many cancers are only found when symptoms reveal themselves or by accident. At that point, cancer is often in late stages when outcomes are poor and there may be fewer treatment options. The Galleri test is a screening test that is added to guideline recommended screening tests.

  • Screening test recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older
  • Screening test detects a signal shared by more than 50 types of cancer and predicts cancer signal origin to help guide diagnostic evaluation

Cancer Signal Detected: The Galleri test detected DNA methylation patterns that are often associated with cancer in the blood sample. A Cancer Signal Detected result is not a diagnosis of cancer. When Galleri detects a cancer signal, diagnostic workup by a qualified healthcare provider, using the standard of care and professional guidelines, is required to establish a cancer diagnosis. In a clinical study, on average, 4 out of 10 (43.1%) of people with a Cancer Signal Detected result received a cancer diagnosis.

No Cancer Signal Detected: The Galleri test did not detect DNA methylation patterns that are associated with cancer. A No Cancer Signal Detected result does not rule out cancer. In a clinical study, fewer than 2 out of 100 (98.5%) of people with a No Cancer Signal Detected result received a cancer diagnosis. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.

No Cancer Signal Detected

The Galleri test is a qualitative, next-generation sequencing screening test for detecting DNA methylation patterns using cell-free DNA isolated from peripheral whole blood.

Whole blood, Streck Cell-Free DNA BCT Tube, 20 mL (2 x 10 mL vials). After draw, whole blood containing Cell-Free DNA BCT should be stored at 18°C to 25°C for up to 7 days total, including shipping.

Follow up diagnostic testing is required to confirm presence of cancer, Biopsy, immunohistochemistry.
2 weeks.
  • Ann Oncol. 2021 Sep;32(9):1167-1177. [PMID: 34176681]
  • Lancet. 2023 Oct 7;402(10409):1251-1260. [PMID: 37805216]
  • Ann Oncol. 2020 Jun;31(6):745-759. [PMID: 33506766]
  • Am Fam Physician. 2022 Oct;106(4):459-460. [PMID: 36260909]
  • Diagnostics (Basel). 2021 Nov 23;11(12):2171. [PMID: 34943407]
  • Diagnostics (Basel). 2022 May 17;12(5):1243. [PMID: 35626398]
  • Cancers (Basel). 2022 Oct 1;14(19):4818. [PMID: 36230741]
  • Streck Cell-Free DNA BCT https://www.streck.com/products/stabilization/cell-free-dna-bct-ivd/#resources
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login